BRAF V600 mutation (THxID BRAF)

Indications

• elibigiblity for treatment of metastatic melanoma with vemurafenib (Zelboraf), dabrafenib (Tafinlar) or trametinib (Mekinist)

Clinical significance

• mutation present in about 1/2 of late-stage melanomas

Procedure

• polymerase chain reaction to identifpoint mutation at Val-600 in the BRAF gene

More general terms

• gene mutation testing; gene mutation analysis

More specific terms

• BRAF V600E mutation
• BRAF V600K mutation

Additional terms

• cutaneous melanoma
• serine/threonine protein kinase B-raf; proto-oncogene B-Raf; p94; v-Raf murine sarcoma viral oncogene homolog B1 (BRAF BRAF1 RAFB1)